Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867800 | 0.82 | CRACR2A (0.54) | CA1CA2 | |
| SCHEMBL5597680 | 0.80 | NPC1 (0.51) | CNR1MAPK1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL5597655 | 0.78 | CNR1 (0.56) | CNR1SMN1; SMN2ALDH1A1RAB9AHTT | |
| SCHEMBL5867747 | 0.78 | RAB9A (0.51) | CA1CA2SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL5597550 | 0.77 | MAPK1 (0.55) | MAPK1PKMHTTLMNA | |
| SCHEMBL5597615 | 0.76 | MAPK1 (0.54) | MAPK1SMN1; SMN2ALDH1A1RAB9APKM | |
| SCHEMBL5597651 | 0.75 | EPHX1 (0.43) | CNR1SMN1; SMN2ALDH1A1RAB9AHTT | |
| SCHEMBL5597931 | 0.75 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL5597596 | 0.74 | NPC1 (0.52) | MAPK1ALDH1A1RAB9APKMNPC1 | |
| SCHEMBL5597942 | 0.74 | TP53 (0.47) | SMN1; SMN2ALDH1A1RAB9AHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | claimed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | claimed |
| JP-2003507328-A | — | — | 2003-02-25 | — | — | JP | claimed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | claimed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | claimed |
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | disclosed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | disclosed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | disclosed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | disclosed |